Bristol Myers Squibb clinches acquisition of Forbius
Adds phase 1 isoform-selective TGF-beta inhibitor AVID200 to pipeline
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Forbius
Bristol Myers Squibb to acquire Forbius
Forbius’s lead TGF-beta asset, AVID200, is an isoform-selective TGF-beta inhibitor, currently in Phase 1 for oncology and fibrosis